Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eledon Pharmaceuticals Inc
(NQ:
ELDN
)
2.060
+0.040 (+1.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
81,544
Open
2.050
Bid (Size)
2.010 (20)
Ask (Size)
2.090 (1)
Prev. Close
2.020
Today's Range
2.000 - 2.080
52wk Range
1.070 - 2.950
Shares Outstanding
22,506,956
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Monday Trading Based on Percentage Gain
April 22, 2024
Via
Investor Brand Network
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023
March 28, 2024
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Performance
YTD
+9.57%
+9.57%
1 Month
N/A
N/A
3 Month
+10.75%
+10.75%
6 Month
+30.38%
+30.38%
1 Year
-1.90%
-1.90%
More News
Read More
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
March 28, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
March 25, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Expert Ratings for Eledon Pharma
November 13, 2023
Via
Benzinga
Kidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To Receive
March 21, 2024
Via
Benzinga
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
March 21, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
January 04, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
November 29, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
November 09, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
November 08, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
November 02, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
October 23, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
October 13, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
October 02, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
September 27, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
September 27, 2023
Via
Benzinga
Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
September 25, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
September 11, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
September 06, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
September 05, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
August 16, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.